A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma

Sied Kebir,Vivien Ullrich,Pia Berger,Celia Dobersalske,Sarah Langer,Laurèl Rauschenbach,Daniel Trageser,Andreas Till,Franziska K Lorbeer,Anja Wieland,Timo Wilhelm-Buchstab,Ashar Ahmad,Holger Fröhlich,Igor Cima,Shruthi Prasad,Johann Matschke,Verena Jendrossek,Marc Remke,Barbara M Grüner,Alexander Roesch,Jens T Siveke,Christel Herold-Mende,Tobias Blau,Kathy Keyvani,Frank K H van Landeghem,Torsten Pietsch,Jörg Felsberg,Guido Reifenberger,Michael Weller,Ulrich Sure,Oliver Brüstle,Matthias Simon,Martin Glas,Björn Scheffler

DOI: https://doi.org/10.1158/1078-0432.CCR-22-0611

2023-01-17

Abstract:Purpose: Therapy resistance and fatal disease progression in glioblastoma are thought to result from the dynamics of intra-tumor heterogeneity. This study aimed at identifying and molecularly targeting tumor cells that can survive, adapt, and subclonally expand under primary therapy. Experimental design: To identify candidate markers and to experimentally access dynamics of subclonal progression in glioblastoma, we established a discovery cohort of paired vital cell samples obtained before and after primary therapy. We further used two independent validation cohorts of paired clinical tissues to test our findings. Follow-up preclinical treatment strategies were evaluated in patient-derived xenografts. Results: We describe, in clinical samples, an archetype of rare ALDH1A1+ tumor cells that enrich and acquire AKT-mediated drug resistance in response to standard-of-care temozolomide (TMZ). Importantly, we observe that drug resistance of ALDH1A1+ cells is not intrinsic, but rather an adaptive mechanism emerging exclusively after TMZ treatment. In patient cells and xenograft models of disease, we recapitulate the enrichment of ALDH1A1+ cells under the influence of TMZ. We demonstrate that their subclonal progression is AKT-driven and can be interfered with by well-timed sequential rather than simultaneous antitumor combination strategy. Conclusions: Drug-resistant ALDH1A1+/pAKT+ subclones accumulate in patient tissues upon adaptation to TMZ therapy. These subclones may therefore represent a dynamic target in glioblastoma. Our study proposes the combination of TMZ and AKT inhibitors in a sequential treatment schedule as a rationale for future clinical investigation.